What are the funding trends in AI revenue cycle management?

All funding deals in the AI revenue cycle management market over the last years

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our report covering the AI revenue cycle management market.

Is AI revenue cycle management funding falling in 2026?

AI revenue cycle management funding is down 37.1% in 2026, but investors are still putting more money into smaller and mid-sized rounds than they did last year.

We counted $352.3 million across 19 funding rounds between January 1 and September 8, compared with $560.2 million across 22 deals during the same period in 2025. The number of funded companies also declined, from 21 to 18.

The headline looks worse because 2025 had some unusually large rounds. Ambience Healthcare raised $243 million, Stedi announced $70 million, and Candid Health secured $52.5 million. Those three transactions represented 65.2% of all funding during the period.

Meanwhile, the median round increased from $8 million to $10 million in 2026. Once we exclude financings exceeding $50 million, investment actually rose 19.3%.

The comparison with 2024 is also useful. Back then, the market attracted $361.7 million across just 13 deals. Capital raised this year is almost identical, but the number of transactions is 46.2% higher. There are more companies raising meaningful amounts than two years ago, even though the market has cooled since 2025.

Funding metric	2026 YTD	2025 YTD	2024 YTD
Total capital	$352.3M	$560.2M	$361.7M
Funding deals	19	22	13
Unique funded companies	18	21	13
Median round	$10.0M	$8.0M	$20.0M
Average round	$18.5M	$25.5M	$27.8M
Largest financing	$120M	$243M	$120M
Capital excluding rounds over $50M	$232.3M	$194.7M	$241.7M
Capital excluding rounds over $100M	$232.3M	$317.2M	$241.7M
Top-three capital concentration	55.3%	65.2%	58.1%

Would AI revenue cycle management funding still be down without the biggest rounds?

Without rounds above $50 million, AI revenue cycle management funding is actually growing. That changes how we should read this year's decline.

The market attracted $232.3 million below that threshold, up from $194.7 million in 2025. Several meaningful financings contributed: Adonis raised $40 million, Lassie secured $35 million, Arintra raised $25 million, and Parallel obtained $20 million.

In 2025, just three transactions accounted for $365.5 million. Ambience Healthcare's $243 million Series C was especially influential, representing 43.4% of the year's comparable-period funding.

There's another detail worth considering. Stedi's August 2025 announcement combined $50 million raised previously with $20 million in new capital. The company explicitly disclosed that structure. Our announcement-date methodology counts the published $70 million headline, but the money was not necessarily all raised during that period.

Removing Stedi's entire announcement would reduce 2025's total to $490.2 million and narrow the reported 2026 decline to 28.1%.

The picture changes again when excluding only rounds above $100 million: funding is still down 26.8%. Stedi's $70 million and Candid Health's $52.5 million remain in that comparison.

So the decline is real, but its severity depends heavily on how we treat the biggest deals. Below $50 million, investors are deploying more capital than last year.

Are fewer AI revenue cycle management startups getting funded?

Yes. Fewer AI revenue cycle management companies are raising capital in 2026, even though the typical financing has become larger.

Our research identified 18 funded companies, compared with 21 during the equivalent period in 2025. Deal volume fell from 22 to 19, while the median financing increased 25%.

The bigger concern is how few new companies are entering the funded startup population.

Only three 2026 deals were classified as first financings, compared with eight in 2025 and five in 2024. Follow-on rounds now represent 84.2% of activity, up from 63.6% last year.

The contrast is clear among recent fundraises. Adonis secured a $40 million Series C, Arintra raised a $25 million Series B, and Candid Health obtained a $120 million Series D. At earlier stages, Parallel, Amperos Health and Procode AI also received follow-on financing.

Companies with previous investors and financing histories are taking a larger share of the available opportunities. Startups raising their first institutional capital appear to be having a harder time.

The first-financing figures rely on publicly traceable funding histories, rather than a complete record of every company's private investments.

Are seed-stage AI revenue cycle management startups being squeezed out?

Seed-stage AI revenue cycle management startups are facing a tougher funding environment, while Series A activity is holding up much better.

Seed deals dropped from ten in 2025 to seven in 2026, and total Seed capital declined from $45.3 million to $26.3 million. The median Seed round stayed close to $4 million, suggesting the main change is the number of financings rather than their typical size.

Series A looks healthier. The number of deals increased from seven to eight, while funding rose from $117 million to $124 million.

Parallel's $20 million Series A is a good example. The company had raised $3.5 million in seed funding the previous year and was already deploying AI agents in hospitals. Amperos Health followed its $4.2 million Seed with a $16 million Series A, while Procode AI raised $4 million in March and another $10 million in July.

These are companies progressing through successive financing rounds rather than entirely new startups appearing for the first time.

Across all stages, Seed and Series A still represent 78.9% of transactions, virtually unchanged from 77.3% in 2025. The market remains heavily early-stage, but there are fewer newly financed businesses within that group.

Financing activity	2026 YTD	2025 YTD	2024 YTD
Total funding deals	19	22	13
First financings	3	8	5
Follow-on financings	16	14	8
First-financing share	15.8%	36.4%	38.5%
Follow-on share	84.2%	63.6%	61.5%
Seed deals	7	10	4
Series A deals	8	7	2
Series B and later deals	3	4	6
Seed + Series A share	78.9%	77.3%	46.2%

Why is denial management suddenly attracting so much AI funding?

Denial management is the fastest-growing part of the AI revenue cycle management funding market in our 2026 comparison, with investors backing several companies rather than just one standout startup.

We identified five denial-management financings totaling $90.8 million, compared with only two rounds worth $7.2 million during the same period in 2025. Its share of total market capital jumped from 1.3% to 25.8%.

Adonis raised $40 million in March, Joyful Health secured $17 million in April, Amperos Health raised $16 million that same month, and Anomaly Insights obtained $17 million in May.

These companies tackle slightly different parts of the problem. Adonis works on reimbursement performance and payment exceptions, Amperos automates denied-claim recovery, while Anomaly Insights helps providers identify reimbursement issues and analyze payer contracts.

Amperos offers one of the clearest examples of why investors are interested. In its April 2026 Series A announcement, the company reported serving more than 3,000 clinical locations and helping recover nearly $700 million annually across more than 500,000 claims.

Hospitals and medical practices lose money when insurers deny claims, underpay providers or delay reimbursement. Software that can recover some of that money offers a result customers can measure.

Bessemer Venture Partners, which led Amperos's financing, estimated in its April 2026 investment analysis that U.S. healthcare providers lose more than $260 billion annually to insurance denials.

It's a powerful pitch: help providers recover revenue they have already earned, and measure the results in dollars.

Is medical coding AI becoming another funding hotspot?

Medical coding AI is attracting more investment in 2026, with five financing events collectively raising $60.2 million, up from $38.5 million across four deals last year.

Arintra secured $25 million in August, Parallel raised $20 million in March, and Procode AI completed two transactions totaling $14 million. Maia Medical Billing also obtained $1.2 million in June.

These startups are taking different approaches.

Arintra builds AI systems for coding and revenue assurance inside health systems. Parallel initially focused on medical coding but is expanding into other administrative work at hospitals. Procode AI combines coding technology with the acquisition of established medical billing businesses, particularly those serving surgical specialists.

The funding is supporting both software platforms and companies using AI to transform existing billing operations.

Parallel provides a concrete sign of adoption. When announcing its Series A, the company said its agents were already deployed across several dozen public and private hospitals.

Procode AI offers a different example. Its July financing was intended partly to fund additional acquisitions, allowing the company to expand beyond plastic surgery and dermatology into other surgical specialties.

Medical coding attracted $163.1 million in the comparable 2024 period, including a recorded $120 million Series C for AKASA. That unusually large financing makes the earlier comparison less representative of the category's typical activity.

Compared with 2025, the category is strengthening through several meaningful financings rather than one giant transaction.

Is claims automation losing investors to denial management?

Claims automation is seeing much narrower funding activity in 2026, while denial management has become a more popular destination for venture capital.

Claims submission and scrubbing attracted only one recorded financing this year: Candid Health's $120 million Series D. In the equivalent 2025 period, five financings raised a combined $177.8 million.

Candid Health is still a major success story. Sixth Street Growth led its July financing, and the company reported 190% year-over-year growth in annual contracted run-rate revenue and 180% net dollar retention during 2025.

Those company-reported operating metrics help explain why a growth investor would commit nine figures.

But the category's broader financing activity has weakened. In 2025, capital also reached Stedi, Camber, Wisdom and Youlify.

The shift toward denial management is interesting because both categories deal with the same underlying reimbursement system. Claims automation tries to improve how claims are prepared and submitted. Denial management focuses on what happens when claims are rejected or payments fall short.

Investors are finding more companies to back on the recovery side of the process. Claims automation still has a major funded player in Candid, but it isn't producing anything close to the same breadth of funding activity.

Which AI revenue cycle management categories are getting the most money now?

Denial management and medical coding are gaining investor attention, while claims submission, patient access and charge capture have become less active compared with 2025.

Denial management increased from two to five deals. Medical coding rose from four to five, with higher total funding and a stronger median round.

Payment posting and reconciliation also appeared as a meaningful funding category, attracting $41.5 million across two deals after recording none during the equivalent 2025 period.

Lassie's $35 million Series A drove most of that increase, while Kubera Health raised $6.5 million to build technology connecting payer contracts with payment operations and reconciliation.

On the weaker side, patient access and eligibility fell from six deals to three. Charge capture and revenue integrity declined from $43.6 million to $10.4 million, despite recording three financings.

Clinical documentation and CDI had no qualifying 2026 transaction in the database. Its 2025 total was entirely driven by Ambience Healthcare's $243 million Series C, making that comparison particularly sensitive to a single fundraising event.

The strongest funding activity is clustering around reimbursement recovery, coding and payment reconciliation.

Category	2026 deals	2026 capital	2025 deals	2025 capital
Denial Management & Appeals	5	$90.83M	2	$7.20M
Medical Coding AI	5	$60.20M	4	$38.50M
Claims Submission & Scrubbing	1	$120.00M	5	$177.80M
Patient Access & Eligibility AI	3	$29.40M	6	$50.15M
Payment Posting & Reconciliation	2	$41.50M	0	$0
Charge Capture & Revenue Integrity	3	$10.39M	4	$43.58M
Clinical Documentation & CDI	0	$0	1	$243.00M
Total market	19	$352.32M	22	$560.23M

Why are investors backing AI that helps hospitals recover payments?

Investors are putting more money into AI reimbursement recovery because these products can show customers exactly how much money they help collect.

Hospitals and medical practices already spend heavily on revenue cycle management, but much of the work still involves checking claims, appealing denials, reviewing contracts and following up with insurers.

Adonis, Amperos Health and Joyful Health are developing products that automate different parts of this process. Arintra works further upstream, helping providers improve coding and identify revenue they might otherwise miss.

One useful indicator comes from Adonis. When announcing its $40 million Series C in March 2026, the company reported more than fourfold revenue growth during 2025 and net revenue retention above 130%.

Amperos has emphasized recovered claims revenue, while Arintra's August financing was positioned around expanding an AI-driven revenue assurance platform.

A hospital CFO can assess reimbursement automation through money recovered, staff time saved and changes in payment performance.

We cannot establish from deal announcements alone that these companies have better margins or retention than every other revenue-cycle category. What we can see is that several are attracting substantial funding while reporting measurable commercial results.

Is AI prior authorization still attracting funding?

AI prior authorization continues to attract venture funding in 2026, although the broader patient access and eligibility category is raising less money than last year.

The category received $29.4 million across three financings, compared with $50.2 million across six deals during the same period in 2025.

GenHealth.ai raised $16.5 million in September, Ethermed secured $8.5 million in April, and Claim Health obtained $4.4 million in January.

GenHealth.ai develops agents that handle healthcare back-office tasks including eligibility, prior authorization, billing and denials. Ethermed focuses on prior-authorization workflows, while Claim Health works on referral intake and admissions.

The regulatory environment gives these products a potentially important tailwind.

Under the Centers for Medicare & Medicaid Services' interoperability and prior-authorization final rule, certain health plans must adopt standardized APIs for electronic prior authorization, generally beginning in January 2027. Other operational requirements began taking effect in 2026.

That creates more reasons for healthcare organizations to modernize how authorization information moves between insurers, providers and software systems.

For now, though, the financing numbers have not followed that potential demand upward. Investors backed fewer companies in the category, and it is too early to call this a new funding boom.

Which AI revenue cycle management startups are getting the biggest checks?

Candid Health, Adonis and Lassie received the largest AI revenue cycle management funding rounds in 2026, showing that investors are still willing to make major commitments to selected companies.

Candid Health leads with $120 million, followed by Adonis at $40 million and Lassie at $35 million.

Arintra's $25 million Series B and Parallel's $20 million Series A come next, followed by denial-management specialists Joyful Health and Anomaly Insights, each with $17 million.

The mix covers claims automation, denial recovery, medical coding, payment administration and hospital workflows. Investors are backing several approaches to automating the revenue cycle.

Candid is the clearest growth-stage example. Sixth Street Growth led its Series D, alongside existing backers including Oak HC/FT, 8VC and Y Combinator.

Lassie shows that large early-stage checks are still possible. Andreessen Horowitz led its $35 million Series A for software automating healthcare-practice administration, starting with dental operations.

Together, the three largest transactions account for $195 million, or 55.3% of the year's funding.

Company	Round	Funding	Main category
Candid Health	Series D	$120M	Claims submission
Adonis	Series C	$40M	Denial management
Lassie	Series A	$35M	Payment reconciliation
Arintra	Series B	$25M	Medical coding
Parallel	Series A	$20M	Medical coding
Joyful Health	Series A	$17M	Denial management
Anomaly Insights	Undisclosed stage	$17M	Denial management
GenHealth.ai	Series A	$16.5M	Patient access
Amperos Health	Series A	$16M	Denial management
Procode AI	Series A	$10M	Medical coding

Are the same venture capital firms dominating AI revenue cycle management?

AI revenue cycle management funding is spread across several venture and growth investors, with no single firm consistently leading the largest deals.

Sixth Street Growth led Candid Health's $120 million Series D, Quadrille Capital led Adonis's $40 million Series C, and Andreessen Horowitz led Lassie's $35 million Series A.

Elsewhere, Define Ventures backed Arintra, Index Ventures led Parallel, Bessemer Venture Partners financed Amperos Health, and Health Velocity Capital led Procode AI's July round.

The investors are financing businesses at very different stages.

Sixth Street is backing an established company with substantial reported commercial growth. Index Ventures is helping Parallel expand deployments of hospital AI agents. Health Velocity Capital is financing Procode's combination of AI software and acquisitions of established billing businesses.

Strategic investors are involved too. Arintra's Series B included Yale New Haven Health's Center for Health Care Innovation and Endeavor Health Ventures. Ethermed's financing included Healthliant Ventures.

Only 15 of the 19 transactions disclosed identifiable lead or co-lead investors in 2026, compared with 21 of 22 in 2025. That limits any firm conclusions about changing investor leadership, and strategic participation remains uneven.

The investor base nevertheless includes both generalist technology investors and firms with direct healthcare industry expertise.

Is AI revenue cycle management funding becoming too concentrated?

AI revenue cycle management funding is less concentrated in its biggest rounds than it was in 2025, even though fewer startups are receiving capital.

The largest deal accounts for 34.1% of the current total, compared with 43.4% last year. The top three rounds represent 55.3%, down from 65.2%, while the top five account for 68.1%, down from 74.5%.

Part of the explanation is simply the absence of another Ambience-sized financing. In 2025, that $243 million Series C dominated the market.

This year's largest rounds are distributed among Candid Health, Adonis, Lassie, Arintra and Parallel.

But funding has not become easier to obtain. The number of distinct companies raising capital has declined, and the first-financing share has fallen sharply.

Investors are spreading the largest checks across a somewhat wider group of established businesses while financing fewer new entrants. That could leave the market with several well-funded leaders and a thinner pipeline of newly financed competitors.

Could 2026 still become a strong year for AI revenue cycle management fundraising?

AI revenue cycle management could still finish 2026 with substantial funding activity, although matching the exceptional capital raised in 2025 would require more large transactions.

By September 8, the market had accumulated $352.3 million across 19 deals.

For context, the entire 2025 calendar year recorded $584.9 million across 26 deals, while full-year 2024 reached $487 million across 19 transactions.

The current year has already matched 2024's complete annual deal count. It has also reached 60.2% of full-year 2025 capital and 72.4% of full-year 2024 capital.

That's a respectable level of activity, especially considering the decline from last year's unusually large rounds.

One major financing could materially change the annual total, however, and fundraising is rarely distributed evenly throughout the year.

The more revealing developments will be whether first financings recover and whether denial-management and coding startups continue raising capital across several different companies.

What is actually changing in AI revenue cycle management funding?

AI revenue cycle management funding is becoming more selective in 2026, with money increasingly going to previously backed companies and startups tackling specific reimbursement problems.

The headline funding decline of 37.1% is partly explained by unusually large 2025 financings. Outside rounds above $50 million, capital deployment is stronger this year.

The more important weakness is the decline in new-company funding. First financings fell from eight to three, while follow-on transactions now make up more than four-fifths of the market. Seed activity has also slowed, even though Series A investment remains relatively healthy.

Denial management has emerged as the clearest winner. Its financing growth is supported by several companies, including Adonis, Joyful Health, Amperos Health and Anomaly Insights. Medical coding is also attracting more attention, with Arintra, Parallel and Procode AI receiving meaningful capital.

Meanwhile, claims automation has become much more dependent on Candid Health, and clinical documentation has yet to produce another financing comparable to Ambience Healthcare's large 2025 round.

Investors appear particularly interested in products that help providers collect money, reduce reimbursement errors and automate expensive administrative work. Company announcements from Adonis, Amperos and Candid also provide some evidence of commercial traction behind this interest.

The next important development will be whether the market starts financing more new startups again. For now, much of the money is going to companies that have already secured backing and can point to concrete progress.